Durvalumab - PharmaKB

Imfinzi(durvalumab)

Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.

Download report

Favorite

Top 200 Pharmaceuticals by Retail Sales

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
neoplasms	D009369
respiratory tract diseases	D012140

Trade Name

FDA

EMA

Imfinzi

Drug Products

FDA

EMA

Reference product - 351(a)

Interchangeable product - 351(k)

Biosimilar product - 351(k)

Durvalumab

Tradename	Proper name	Company	Number	Date	Products
Imfinzi	durvalumab	AstraZeneca	N-761069 RX	2017-05-01	2 products

Labels

FDA

EMA

Brand Name	Status	Last Update
imfinzi	Biologic Licensing Application	2026-05-28

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
transitional cell carcinoma	—	D002295	—

Agency Specific

FDA

EMA

Expiration	Code
durvalumab, Imfinzi, AstraZeneca UK Ltd
2029-10-21	Orphan excl.

Patent Expiration

No data

ATC Codes

L: Antineoplastic and immunomodulating agents

— L01: Antineoplastic agents

— L01F: Monoclonal antibodies and antibody drug conjugates

— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors

— L01FF03: Durvalumab

HCPCS

Code	Description
J9173	Injection, durvalumab, 10 mg

Clinical

Clinical Trials

897 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Non-small-cell lung carcinoma	D002289	—	—	44	121	40	3	24	218
Lung neoplasms	D008175	—	C34.90	34	91	14	2	20	144
Neoplasms	D009369	—	C80	51	44	3	2	7	91
Neoplasm metastasis	D009362	EFO_0009708	—	13	9	4	1	—	24
Pneumonia	D011014	EFO_0003106	J18	—	1	—	1	1	3
Oncogenes	D009857	—	—	—	—	—	1	1	2
Meningeal carcinomatosis	D055756	EFO_1001012	—	—	—	—	1	—	1

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Carcinoma	D002277	—	C80.0	35	72	9	—	6	104
Hepatocellular carcinoma	D006528	—	C22.0	18	51	10	—	14	84
Small cell lung carcinoma	D055752	—	—	15	47	11	—	12	81
Liver neoplasms	D008113	EFO_1001513	C22.0	18	47	9	—	10	74
Breast neoplasms	D001943	EFO_0003869	C50	32	43	4	—	1	65
Biliary tract neoplasms	D001661	—	C24.9	10	28	8	—	5	45
Squamous cell carcinoma of head and neck	D000077195	—	—	18	25	3	—	1	40
Squamous cell carcinoma	D002294	—	—	19	23	3	—	2	38
Cholangiocarcinoma	D018281	—	C22.1	9	31	1	—	1	38
Urinary bladder neoplasms	D001749	—	C67	11	27	5	—	—	37

Show 22 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pancreatic neoplasms	D010190	EFO_0003860	C25	21	26	—	—	1	38
Colorectal neoplasms	D015179	—	—	18	28	—	—	—	38
Adenocarcinoma	D000230	—	—	10	31	—	—	—	34
Triple negative breast neoplasms	D064726	—	—	15	21	—	—	—	30
Melanoma	D008545	—	—	12	11	—	—	2	21
Stomach neoplasms	D013274	EFO_0003897	C16	8	14	—	—	1	18
Esophageal neoplasms	D004938	—	C15	6	14	—	—	1	17
Lymphoma	D008223	—	C85.9	11	8	—	—	—	16
Prostatic neoplasms	D011471	—	C61	6	12	—	—	—	15
Ovarian epithelial carcinoma	D000077216	—	—	5	9	—	—	—	12

Show 118 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Primary myelofibrosis	D055728	—	D47.4	2	—	—	—	—	2
Central nervous system neoplasms	D016543	—	—	2	—	—	—	—	2
Myeloproliferative disorders	D009196	—	D47.1	1	—	—	—	—	1
Precursor cell lymphoblastic leukemia-lymphoma	D054198	—	C91.0	1	—	—	—	—	1
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	1	—	—	—	—	1
Myelomonocytic leukemia chronic	D015477	—	C93.1	1	—	—	—	—	1
Anemia	D000740	EFO_0004272	D64.9	1	—	—	—	—	1
Leukemia myeloid chronic atypical bcr-abl negative	D054438	—	C92.2	1	—	—	—	—	1
Myelodysplastic-myeloproliferative diseases	D054437	—	—	1	—	—	—	—	1
Myeloid leukemia chronic-phase	D015466	—	—	1	—	—	—	—	1

Show 22 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myocarditis	D009205	—	I51.4	—	—	—	—	3	3
Heart diseases	D006331	EFO_0003777	I51.9	—	—	—	—	2	2
Autoimmune diseases	D001327	EFO_0000540	M30-M36	—	—	—	—	2	2
Cardiovascular diseases	D002318	EFO_0000319	I98	—	—	—	—	1	1
Cardiomyopathies	D009202	EFO_0000318	I42	—	—	—	—	1	1
Pericarditis	D010493	EFO_0007427	I30	—	—	—	—	1	1
Vasculitis	D014657	EFO_0006803	M31	—	—	—	—	1	1
Human influenza	D007251	EFO_0007328	J11.1	—	—	—	—	1	1
Myositis	D009220	EFO_0000783	G72.49	—	—	—	—	1	1
Drug-related side effects and adverse reactions	D064420	—	T88.7	—	—	—	—	1	1

Show 14 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Durvalumab
INN	durvalumab
Description	Durvalumab (human mab)
Classification	Antibody
Drug class	monoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	>5X8M:B\|durvalumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH >5X8M:C\|durvalumab light chain EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC